Methods of cancer treatment using naaladase inhibitors

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 31/66 (2006.01) A61K 31/00 (2006.01) A61K 31/665 (2006.01) A61K 31/67 (2006.01) A61K 31/675 (2006.01) A61K 38/05 (2006.01) A61K 38/06 (2006.01) A61K 45/06 (2006.01) C07F 9/30 (2006.01) C07F 9/38 (2006.01)

Patent

CA 2257433

The present disclosure relates to dipeptidase inhibitors, and more particularly, to novel methods of using phosphonate derivatives, hydroxyphosphinyl derivatives, and phosphoramidate derivatives to inhibit N- Acetylated .alpha.-Linked Acidic Dipeptidase (NAALADase) enzyme activity, and to treat prostate diseases, especially using the compounds of the present invention for the inhibition of the growth of prostate cancer cells.

La présente invention concerne des inhibiteurs de la dipeptidase, et plus particulièrement, de nouvelles méthodes d'utilisation des dérivés phosphonate, des dérivés hydroxyphosphinyle, et des dérivés phosphoramidate pour inhiber l'activité de la dipeptidase acide à liaison .alpha.N-acétylée (NAALADase), et pour traiter les affections de la prostate, notamment à l'aide des composés de la présente invention pour inhiber la croissance des cellules cancéreuses de la prostate.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Methods of cancer treatment using naaladase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods of cancer treatment using naaladase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of cancer treatment using naaladase inhibitors will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1460964

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.